Compare · LQDA vs TVTX
LQDA vs TVTX
Side-by-side comparison of Liquidia Corporation (LQDA) and Travere Therapeutics Inc. (TVTX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both LQDA and TVTX operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- TVTX is the larger of the two at $6.32B, about the same size as LQDA ($6.31B).
- TVTX has been more active in the news (11 items in the past 4 weeks vs 10 for LQDA).
- TVTX has more recent analyst coverage (25 ratings vs 17 for LQDA).
- Company
- Liquidia Corporation
- Travere Therapeutics Inc.
- Price
- -
- -
- Market cap
- $6.31B
- $6.32B
- 1M return
- -17.64%
- -
- 1Y return
- +157.68%
- -
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2018
- News (4w)
- 10
- 11
- Recent ratings
- 17
- 25
Liquidia Corporation
Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its product candidates include LIQ861, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension; and LIQ865, a sustained-release formulation of bupivacaine for the treatment of local post-operative pain. The company also distributes generic treprostinil injection in the United States. Liquidia Corporation was founded in 2004 and is headquartered in Morrisville, North Carolina.
Travere Therapeutics Inc.
Travere Therapeutics, Inc., a biopharmaceutical company, focuses on the identification, development, and commercialization of therapies for the treatment of rare diseases. Its marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid for the treatment of radiolucent stones in well-opacifying gallbladders; Cholbam, a cholic acid capsule to treat pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects, as well as for adjunctive treatment of patients with peroxisomal disorders; and Thiola and Thiola EC, a tiopronin tablet for the treatment of homozygous cystinuria. The company's product candidates also consist of Sparsentan, which is in Phase III clinical trial for the treatment of focal segmental glomerulosclerosis and immunoglobulin A nephropathy; and TVT-058, a novel investigational human enzyme replacement candidate, which is in Phase I/II clinical trials for the treatment of classical homocystinuria. It has a cooperative research and development agreement with National Institutes of Health's National Center for Advancing Translational Sciences, and Alagille Syndrome Alliance for identification of potential small molecule therapeutics for NGLY1 deficiency and Alagille syndrome. The company was formerly known as Retrophin, Inc. and changed its name to Travere Therapeutics, Inc. in November 2020. Travere Therapeutics, Inc. was incorporated in 2008 and is headquartered in San Diego, California.
Latest LQDA
- Chief Business Officer Adair Jason exercised 31,799 shares at a strike of $11.00 and sold $5,087,225 worth of shares (73,631 units at $69.09) as part of a pre-agreed trading plan, decreasing direct ownership by 19% to 174,606 units (SEC Form 4)
- SEC Form 144 filed by Liquidia Corporation
- Director Rielly-Gauvin Katherine exercised 55,182 shares at a strike of $2.54 and sold $4,087,435 worth of shares (55,182 units at $74.07) (SEC Form 4)
- Chief Medical Officer Saggar Rajeev sold $5,972,206 worth of shares (79,534 units at $75.09) and exercised 50,000 shares at a strike of $3.73, decreasing direct ownership by 17% to 142,265 units (SEC Form 4)
- SEC Form 144 filed by Liquidia Corporation
- Amendment: SEC Form SCHEDULE 13G/A filed by Liquidia Corporation
- SEC Form 10-Q filed by Liquidia Corporation
- Liquidia Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Other Events, Financial Statements and Exhibits
- Liquidia Corporation Reports Second Quarter 2026 Financial Results
- Amendment: SEC Form SCHEDULE 13G/A filed by Liquidia Corporation
Latest TVTX
- Director Lyons Gary A exercised 10,000 shares at a strike of $17.44 and sold $632,846 worth of shares (10,000 units at $63.28) as part of a pre-agreed trading plan (SEC Form 4)
- SEC Form 144 filed by Travere Therapeutics Inc.
- SEC Form 144 filed by Travere Therapeutics Inc.
- Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- SEC Form SCHEDULE 13G filed by Travere Therapeutics Inc.
- SEC Form SCHEDULE 13G filed by Travere Therapeutics Inc.
- Amendment: SEC Form SCHEDULE 13G/A filed by Travere Therapeutics Inc.
- Travere Therapeutics to Participate at Upcoming Investor Conferences
- SEC Form 10-Q filed by Travere Therapeutics Inc.
- Travere Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits